A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.

Twenty-Eight (28) subjects (12 for cohort 1 and 16 for cohort 2 ) will be included in the study. Subjects in each cohort will be injected with a different dose of RZL-012. The total of 28 subjects will be enrolled in 2 clinical sites.

Study Overview

• Status: Completed
• Conditions: Submental Fat
• Intervention / Treatment: Drug: Placebo; Drug: RZL-012

Detailed Description

This is a single blinded, randomized, placebo-controlled, 2-cohort clinical study in healthy volunteers. Cohort 1 will be comprised of 8 active (RZL-012) and 4 placebo subjects. Cohort 2 will be comprised of 16 subjects wuth at least 4 placebo subjects. All subjects will receive a single dose of RZL-012 or vehicle into the submental area, after which they will be monitored for safety and efficacy during 84 days of follow-up.

Subjects will be blinded to study treatment while physicians will not be blinded.

The study will be composed of 2 treatment cohorts, 12 in cohort 1 and 16 in cohort 2.

The study will be conducted in 2 clinical sites. Per each study cohort, subjects will be randomized to receive active or placebo treatment according to a randomization program that will be prepared prior to study initiation. Each clinical site will have at least one active and one placebo treatment subject per each study cohorts. In case of slow enrollment in one of the sites, other sites may complete the enrollment of subjects in each cohort.

Cohort 1 (N=12) - Each subject will be dosed with up to 120 mg RZL-012 (depending on submental fat area) or vehicle.

Cohort 2 (N=16) - Each subject will be dosed with up to 240 mg RZL-012 (depending on submental fat area) or vehicle.

Treatment of cohort 2 will start following cohort 1 day 28 data. An independent Data Safety Monitoring Board (DSMB) will review safety and tolerability data for cohort 1 subjects, 28 days after injection, and decide whether it is safe to increase the dose for the next study cohort. The decision to proceed to the cohort 2 will be made within 30 days (28 days + 2 days) after injection of the last dosed subject in cohort 1.

The DSMB will be comprised of two independent MDs with expertise in the aesthetic area and in conduction of clinical trials.

In case of serious safety concerns (e.g. prolonged severe swelling or severe pain following injection) among cohort 1 subjects receiving the 120mg dose, sponsor and DSMB may decide to reduce or stay with the 120mg/subject dose level for cohort 2 subjects.

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60611
      • DeNova Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Men and women 18-65 years old.
2. Subjects with Body Mass Index <35
3. Subjects must have submental skin fold thickness greater than 1.5 cm as measured with calipers.
4. Males must be willing to be clean shaved for all study visits.
5. Patient weight must be stable (no fluctuation of >15 pounds in the past year)
6. Males or females in the age of fertility agree to use a double-barrier contraceptive device (e.g., condom and spermicide) for 4 weeks after treatment with RZL 012.
7. Subjects must be able to adhere to the visit schedule and protocol requirements and be available to complete the study.
8. Subjects must sign an IRB approved informed consent indicating they are aware of the investigational nature of the study.

Exclusion Criteria:

Subjects meeting any of the following criteria will be excluded from study participation:

1. Unable to tolerate subcutaneous injection.
2. Pregnant or lactating women.
3. Subjects with dysfunctional gallbladder activity, e.g. underwent cholecystectomy or cholecystitis.
4. Any uncontrolled systemic disease -a potential patient in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study
5. Treatment with botulinum toxin injections in the neck or chin area within 6 months before screening.
6. Excessive submental skin laxity.
7. Any Scars, unshaven hair, tattoos or jewelry on or near the proposed treatment area
8. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study
9. An active dermatitis or open wound in the proposed treatment area
10. An active bacterial, fungal, or viral infection in the proposed treatment area
11. Pre-existing skin condition in the submental region that may confound evaluation or analysis, at investigator discretion
12. Previously treated with focused ultrasound, radiofrequency, cryolipolysis, liposuction, sodium deoxycholate to the submental region within the previous 6 months
13. Pre-existing neurological or gastrointestinal condition leading to dysphagia, dysphonia or facial nerve palsy
14. Pre-existing medical condition other than increased submental fat that may result in increased submental fullness such as but not limited to thyroid enlargement, goiter, cervical lymphadenopathy etc., at investigator discretion
15. Must not have a planned fat reduction procedure of any variety to the submental region for the duration of the study
16. Must not have planned significant alterations in diet or physical activity that may result in significant fluctuations in weight.
17. Subjects with medication or history of coagulopathy.
18. Allergic subjects to Bendaryl.
19. Subjects treated chronically at least 3 months prior to study entry with systemic steroids or immunosuppressive drugs.
20. Subjects treated chronically at least one week prior to study entry with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
21. Current participation or participation within 3 months prior to the start of this study in a drug or other investigational research study.
22. Claustrophobia or MRI incompatible device or implant.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: RZL-012; A single-treatment injection, multiple subcutaneous injections of RZL-012 administered into 48 sites in the submental fat (0.05/0.1mL per site): Up to 120mg administered at 48 sites in a volume of 0.05 ml at each injection site (total injected volume 2.4mL); Up to 240 mg administered at 48 sites in a volume of 1 ml at each injection site (total volume injected 4.8mL)	Drug: RZL-012; Subcutaneous injection to the submental fat area
Placebo Comparator: Vehicle; Subject receive a single-treatment injection. Multiple injections of the Placebo are administered at 48 sites (0.05/0.1mL per site) into the submental fat. Up to a total of 2.4 mL will be injected for placebo subjects enrolled during cohort 1. Up to a total of 4.8 mL will be injected for placebo subjects enrolled during cohort 2.	Drug: Placebo; Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety: Adverse Events Follow up	To evaluate the safety of RZL-012 subcutaneous injections in the submental area, relative to placebo, as assessed by spontaneous adverse event reports and post injection evaluation of subjects. Specifically, Pain, Induration, Bruising, Erythema and Edema will be closely followed up following treatment.	0-84 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Physician's Global Assessment	Evaluation of treatment efficacy by using Physician's global assessment questionnaire for active vs. placebo subjects, on study Day 84	0-84 days
Efficacy: MRI Volume Reduction	Reduction from baseline in submental fat volume, as measured with MRI, in RZL-012 treated subjects vs. placebo treated subjects on Day 84 following injection.	0-84 days
Efficacy: Improvement in Face Satisfaction Questionnaire - A Score From 0 (Worst) to 100 (Best) Marks the Subject's Satisfaction	Improvement from baseline in the Faceq satisfaction questionnaire rating score in RZL-012 treated subjects vs. placebo treated subjects on day 84.	0-84 days

Collaborators and Investigators

• Sponsor: Raziel Therapeutics Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): February 25, 2020
• Primary Completion (Actual): September 16, 2020
• Study Completion (Actual): September 16, 2020

Study Registration Dates

• First Submitted: September 10, 2019
• First Submitted That Met QC Criteria: September 11, 2019
• First Posted (Actual): September 12, 2019

Study Record Updates

• Last Update Posted (Actual): November 18, 2023
• Last Update Submitted That Met QC Criteria: October 31, 2023
• Last Verified: September 1, 2019

More Information

Terms related to this study

• Other Study ID Numbers: RZL-012-SMF-P2aUS-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No